Wuhan Zhongzhi Biotechnologies INC. (ZBI), located in Wuhan, China, was founded in 2011. As a national High-Tech enterprise, ZBI provides customers with multiplex and rapid molecular diagnostic reagents, supporting instruments, and comprehensive nucleic acid detection solutions.

        ZBI is the exclusive domestic innovative enterprise for multiplex detection and rapid detection of nucleic acid RNA pathogens, is an important security enterprise for epidemic prevention and control in Hubei, and an important enterprise for the production of medical epidemic prevention materials in Wuhan. At the beginning of the Covid-19 breakthrough, ZBI, as a representative molecular diagnostic enterprise in Hubei, first developed two 2019-nCoV nucleic acid detection kits based on RNA technology platforms, which were approved by NMPA.

        ZBI has four patent technology which satisfied the diversity requirement for clinical and laboratory use. The Dual Amplification technology (DAT) platform devoted to test multiplex pathogens; the RNA Amplification-Lateral Flow Assay (RGT) devoted to improve the speed of testing that completed test within 1 hour. Moreover, there are multiplex micro-RNA detection for RNA Early detection and Multiplex Biotic Signal Amplification (MBSA) for high sensitivity detection.

        ZBI is an ISO 13485 certified company with CE certified products. The majority of products are registered with NMPA class Ⅲ medical devices and CE certification. The company focuses on the detection of infectious pathogens by nucleic acid and is dedicated to "improving the quality of diagnosis and care of life and health". The strategy of market orientation, the concept of pioneer products and the tactics of high quality and advanced technology have made the company one of the most professional enterprises in the field of multiplex and rapid detection of respiratory pathogens in China.